Yale Bulletin and Calendar

September 16, 2005|Volume 34, Number 3


BULLETIN HOME

VISITING ON CAMPUS

CALENDAR OF EVENTS

IN THE NEWS

BULLETIN BOARD

CLASSIFIED ADS


SEARCH ARCHIVES

DEADLINES

DOWNLOAD FORMS

BULLETIN STAFF


PUBLIC AFFAIRS HOME

NEWS RELEASES

E-MAIL US


YALE HOME PAGE


Medical school offering clinical trial of
new treatment for multiple sclerosis

The School of Medicine is participating in the first clinical trial testing atorvastatin to delay or decrease disease in patients who have experienced a first attack of multiple sclerosis (MS).

Statins, of which atorvastatin is one, are a relatively new group of drugs used to lower cholesterol levels. Researchers believe statins may affect the immune system, reducing brain inflammation associated with MS.

To be eligible to enroll in the trial, which is being conducted at 15 sites nationwide, individuals must have experienced a first attack, or clinically isolated syndrome (CIS), lasting at least 48 hours and involving either the optic nerve, spinal cord, brain stem or cerebellum.

"Because permanent neurologic damage can occur during the CIS stage, researchers are seeking new treatments," says Dr. Jana Preiningerova, assistant professor in the Department of Neurology. "Currently, interferon is the only approved therapy for CIS patients, but it has reported side effects and is administered through weekly intra-muscular injections. Atorvastatin, if proven to be effective, can be taken orally and has an established tolerance profile, making it an attractive candidate for patients who need long-term treatment."

The primary objective of the trial is to evaluate the ability of atorvastatin to decrease or delay clinical and MRI-detected disease activity in patients with CIS and MRI findings suggestive of early MS, compared with placebo.

This trial will also examine whether early intervention in patients with CIS may result in a state of immunological tolerance and whether statins have any residual effect after discontinuation.

The trial is being conducted by the Immune Tolerance Network, which is sponsored by the National Institute for Allergy and Infectious Diseases. Sarah Harma is the study coordinator at the School of Medicine. Those interested in participating in the trial can contact her at (203) 764-8160 or sarah.harma@yale.edu.


T H I SW E E K ' SS T O R I E S

Yale community extends helping hand to the victims of Hurricane Katrina

Yale leaders contribute $70,000 to match employee and student donations

Student donates prize money to aid victims of hurricane

Panel examined why Katrina was 'a perfect storm' of failure

Brenzel named undergraduate admissions dean

Studies explore function and formation of feathers

Chinese president's visit postponed

ENDOWED PROFESSORSHIPS

NBA star to discuss his humanitarian efforts in the Congo

Director Sofia Coppola to give Chubb Lecture

Labor-management training aims to foster cooperation

Project explores how cultural outlook impacts opinions

MEDICAL SCHOOL NEWS

'Days of Caring'

Event celebrates 400-year anniversary of 'Don Quixote'

Symposium to examine history of U.S. reach into the Pacific

Scientist Pan invited to participate in NAE symposium

Electrical engineer T.P. Ma is honored for solid-state research

In weekly series, World Fellows will debate global topics

University will celebrate Constitution Day on Sept. 20

Multimedia artist presents photo exhibit and video installation at ISM

'A Taste of Bulgaria' to aid flood victims in another corner of the world

Urban infra-power and urban charisma to be explored in conference

Search committee named for School of Art dean

Biophysical chemist Julian Sturtevant . . .

Memorial service scheduled for . . . Robert Abelson

Alumni magazine now reaches every Yale graduate in the U.S.

Campus Notes


Bulletin Home|Visiting on Campus|Calendar of Events|In the News

Bulletin Board|Classified Ads|Search Archives|Deadlines

Bulletin Staff|Public Affairs|News Releases| E-Mail Us|Yale Home